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Iron chelation therapy is often used to treat iron overload in patients requiring transfusion of red blood cells (RBC). A 76-
year-old man with MDS type refractory cytopenia with multilineage dysplasia, intermediate-1 IPSS risk, was referred when he
became transfusion dependent. He declined infusional chelation but subsequently accepted oral therapy. Following the initiation
of chelation, RBC transfusion requirement ceased and he remained transfusion independent over 40 months later. Over the same
time course, ferritin levels decreased but did not normalize. There have been eighteen other MDS patients reported showing
improvement in hemoglobin level with iron chelation; nine became transfusion independent, nine had decreased transfusion
requirements, and some showed improved trilineage myelopoiesis. The clinical features of these patients are summarized and
possible mechanisms for such an eﬀect of iron chelation on cytopenias are discussed.
1.Introduction
The myelodysplastic syndromes (MDS) are characterized by
ineﬀective hematopoiesis, cytopenias, and a risk of transfor-
mation to acute myeloid leukemia (AML); survival and AML
risk are predicted by the International Prognostic Scoring
System (IPSS) [1]. Because the median age of the MDS onset
is in the seventh decade, most patients are ineligible for
potentially curative hematopoietic stem cell transplantation
[2]. Although other treatments are now available [3–7],
the standard treatment for many MDS patients remains
supportive care.
Most MDS patients eventually become red blood cell
(RBC) transfusion dependent, risking iron overload [8],
which may lead to cardiac, hepatic, and endocrine dysfunc-
t i o n .R e c e n ts t u d i e ss u g g e s ta na d v e r s ee ﬀect of RBC trans-
fusion dependence on survival, predominantly in lower-risk
MDS [9]. This eﬀect was suﬃciently signiﬁcant that RBC
transfusion dependence was incorporated into the World
Health Organization Prognostic Scoring System (WPSS) for
MDS [10].
While the beneﬁts of iron chelation therapy are better
established in thalassemia [11], recent retrospective studies
in lower-risk MDS suggest a possible improvement in
survival in transfusion dependent patients who received
chelation [12]. Guidelines in MDS recommend chelation
with an otherwise reasonable life expectancy and evidence
of iron overload: elevated serum ferritin, iron related organ
dysfunction, or chronic RBC transfusions [13, 14]. We
present the clinical course of a RBC transfusion dependent
MDS patient who became transfusion independent shortly
after starting chelation and has remained transfusion inde-
pendent for over three years. We review the literature on
the abrogation of cytopenias in acquired anemias following
chelation.
This paper was prepared in accordance with the require-
ments of the St. Paul’s Hospital Institutional Research Ethics
Board.2 Advances in Hematology
2.CaseReport
A 76-year-old man was referred in June 2004. He was
diagnosed with MDS in 1997 during a work-up of abnormal
bloodcounts:whitebloodcells(WBC)2.4(normal4.0–11.0)
× 109/L, neutrophils 0.7 (2.0–8.0) × 109/L, hemoglobin
(Hb) 133 (135–180)G/L, and platelets 108 (150–400)
× 109/L. The following laboratory parameters were nor-
mal: creatinine, bilirubin, thyroid stimulating hormone,
reticulocyte count, serum B12 level, red blood cell folate;
and serum protein electropheresis. Bone marrow aspiration
and biopsy showed refractory anemia (RA) by the French-
American-British (FAB) classiﬁcation [15] and cytogenetic
analysis revealed trisomy 8 and loss of chromosome Y.
Stem cell culture showed no erythropoietin independent
colonygrowth,serumerythropoietinlevelwas148.3(normal
3.3–16.6)IU/mL and IPSS score was intermediate-1. He
remained transfusion independent until one month prior to
referral, when the hemoglobin was 60G/L, prompting the
initiation of RBC transfusion support.
History and physical examination were otherwise unre-
markable. WBC count at referral was 3.4 × 109/L, Hb
(transfused) 86G/L, mean cellular volume (MCV) 121ﬂ
(80–100), and platelets 44 × 109/L. Serum ferritin was 1293
(15–370)ug/L with no prior ferritin levels available. Bone
marrow aspiration and biopsy conﬁrmed RA/refractory
cytopenia with multilineage dysplasia (RCMD) by World
Health Organization (WHO) criteria [16]. Marrow blast
count was 2%.
Over a 30-month period, he required transfusion of
3 RBC units every 4 weeks to maintain the hemoglobin
above 90G/L and he complained of fatigue and functional
limitation; he received approximately 90 RBC units in
total. In January 2005, the ferritin was 2197ug/L but
he declined deferoxamine; however, in September 2006,
he agreed to start deferasirox. Bone marrow aspiration
and biopsy showed unchanged RCMD and karyotype.
Deferasirox was started at 20mg/kg/day. He required several
dose interruptions and adjustments for renal insuﬃciency
(peak creatinine 141umol/L, normal to 100umol/L) and the
dose of deferasirox was titrated between 5–30mg/kg/day. He
received no other treatment for anemia.
Two months after starting chelation, the hemoglobin
increased to 109G/L and he has not required transfusion
since. Mean hemoglobin over 24 months was 122 (range
96–144)G/L. Hemoglobin and ferritin levels are shown
in Figure 1. The patient reports excellent energy and a
signiﬁcantly improved quality of life.
In May 2008, he was assessed for skin nodules and
reported having similar nodules that appeared and regressed
spontaneously for at least two years. A biopsy revealed
leukemia cutis (LC). Despite this, he remained clinically
well and transfusion independent for 17 months since the
diagnosis of LC, over 41 months since the initial appearance
of nodules, and 40 months since the initiation of chelation.
Characteristics of ten MDS patients, including ours,
achieving transfusion independence with chelation are sum-
marized in Table 1 [17–19]. Nine other patients with signiﬁ-
cant improvement in hemoglobin with chelation have been
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Figure 1: Hemoglobin and serum ferritin levels for a patient
with MDS receiving iron chelation therapy. The solid black arrow
represents the date at which chelation was initiated and the dashed
arrow represents the date of his last red blood cell transfusion. The
grey bar indicates the period during which transfusion requirement
was 3 red blood cell units every 4 weeks.
reported [19, 20]. Several features of these latter patients
were not reported; however, eight received deferoxamine and
one deferasirox, and the median time to improvement in
RBCtransfusionrequirementwas14.4 (3–24) months. None
of these patients were reported to have received any MDS
treatment other than chelation.
3. Discussion
It is well established that chelation extends the survival of
transfusion dependent patients with thalassemia by mitigat-
ing iron toxicity [21–24]. Recent retrospective data suggest
a possible association between chelation and improved
survival in MDS [12, 25]. The ﬁrst report of decreased
transfusion requirements with chelation was in 1990 [26].
Since then, nineteen MDS patients, including ours, are
reported who had an improvement in hemoglobin or
decreased transfusion requierements.
Our patient was transfusion independent within two
months of starting chelation. The ferritin level decreased
from 5271 to 1225ug/L but remains elevated. Once trans-
ferrin is saturated, non-transferrin bound iron (NTBI) may
be detected [27], correlating with the presence of potentially
cytotoxic reactive oxygen species (ROS) [28]. Whether
oxidative stress was present in our patient is unknown as
few transferrin saturations were recorded and NTBI and
ROS measurement are not readily available. However, the
elevated ferritin over a long course despite chelation while
transfusionindependent may indicate asigniﬁcant iron load,Advances in Hematology 3
Table 1: Clinical characteristics of 10 MDS patients achieving red blood cell transfusion independence with iron chelation therapy.
Clinical Feature (units) n
Age at MDS diagnosis (years) Median 58 (range 18–74)
Gender M : F 5:5
MDS subtype (FAB or WHO)
RA 5
RARS 2
RCMD 1
RAEB 2
IPSS score
Low 1
Intermediate-1 5
Intermediate-1 or 2 1
High 1
Not available 2
Iron chelation agent
Deferoxamine 7
Deferasirox 3
Time to RBC transfusion independence (months) Median 17.5 (range 1–24)
Duration of RBC transfusion independence (months) Median 13 (range 3–40)
Abbreviations: F: female; FAB: French-American-British; IPSS: International Prognostic Scoring
S y s t e m ;M :m a l e ;n: number; RA: refractory anemia; RARS: refractory anemia with ringed sideroblasts,
RAEB: refractory anemia with excess blasts; RBC: red blood cell; RCMD: refractory cytopenia with multilineage dysplasia; and WHO: World Health
Organization.
potentially leading to marrow toxicity and suppression of
hematopoiesis.
A patient with primary myeloﬁbrosis (PMF) was
reported whose hemoglobin increased from 76 ± 10G/L to
100G/L after starting chelation [19]; it returned to baseline
(80G/L) when chelation was interrupted, and increased
again to 100G/L when chelation resumed. A second PMF
patient with baseline hemoglobin 60G/L requiring 2 RBC
units every two weeks achieved long-term transfusion inde-
pendence one month after beginning deferiprone [29]. A
third PMF patient with baseline hemoglobin 50–60G/L
requiring 2-3 RBC units per month became transfusion
independent two months after starting deferasirox, an eﬀect
which persisted two years after chelation was stopped
for improvement in ferritin (953ug/L) and transferrin
saturation (45%) [30]. These patients received no other
treatmentforPMF.Apatientwithaplasticanemia(initialHb
45G/L, neutrophil count 0.3 × 109/L, and platelet count 3 ×
109/L) had trilineage recovery and became RBC transfusion
independent after four years of deferoxamine [31]; this
patient received low-dose erythropoietin following an initial
improvement in blood counts.
An improvement in MCV, platelet and white blood cell
counts was also noted [18, 20]. In a report of six patients,
two with pancytopenia had signiﬁcant increases in WBC,
neutrophil,andplateletcounts(P ≤ .001)[20],seenwithin3
months, maximized by 18 months, and in some patients, the
eﬀect persisted after chelation was discontinued. All of them
had an elevated MCV prior to chelation, which decreased in
ﬁveandnormalizedintwo,suggestingpossibleimprovement
in erythropoiesis outside the MDS clone. In a report of
eleven patients, the neutrophil count increased in eight of
nine, and the platelet count in seven of eleven [18]. In our
patient, recent WBC counts range between 3.1–4.3 × 109/L
and platelets consistently clump; the MCV is unchanged at
120ﬂ.
The mechanisms by which chelation may improve
cytopenias are unclear; however, iron was recently shown to
have a suppressive eﬀect on erythroid progenitors in vitro
[32]. Erythroid colony assays on 42 MDS patients showed,
in patients with ferritin 250ug/L or more, that BFU-E were
a mean of 2.35 (range 0–27) colonies per culture, compared
to 10.1 (0–76) in patients with normal ferritin (P<. 004);
whether this is an eﬀect of iron or due to other factors awaits
further study.
Although chelation may exert its protective eﬀect by
reversingthedepositionofiron[23,33],oxidativestressfrom
iron overload may damage lipids, proteins, and nucleic acids
[27, 28, 34–37], and it would be interesting to determine
whether the protective eﬀect of chelation on BFU-E might be
from oxidative stress alleviation. A study of 15 patients with
lower-risk MDS showed a decrease in RBC ROS following
three months of chelation [38] and a relationship between
ferritinandROScontentofCD34+cellsinMDSpatientswas
established [39]. In thalassemia, chelation reduced oxidation
in RBC and increased half-life from 12.1 ± 2.4t o1 6 .4 ± 4.3
days [40]. In the US03 trial of deferasirox in MDS, hema-
t o l o g i ci m p r o v e m e n tw a ss e e ni n5o f5 3p a t i e n t s( 9 . 4 % )
[41] and LPI, an indicator of oxidative stress, normalized
over 12 months of chelation; whether this accounts for the
mitigation of cytopenias remains to be determined. Finally,
there are reports of increased erythropoietin levels with4 Advances in Hematology
chelation in normal volunteers and this could contribute to
an improvement in hemoglobin in MDS [3, 42].
It has been suggested that the transcription factor NF-κB
may be important in modifying myelopoiesis with chelation.
In mononuclear cells of MDS patients [43], deferasirox
induced a signiﬁcant reduction in NF-κB activity, but the
opposite eﬀect was seen with deferoxamine and deferiprone
and no diﬀerence was noted in patients with or without iron
overload. Although these ﬁndings might explain an eﬀect
of deferasirox on cytopenias, the eﬀect of deferoxamine and
deferiprone is not accounted for [18].
Sloand et al. showed improvement in erythropoiesis
within the MDS clone in patients with trisomy 8 responding
to immunosuppressive therapy [44]. While our patient has
+8, no therapy other than chelation was administered;
however, the MCV remains elevated, possibly indicating a
signiﬁcant contribution to erythropoiesis by the MDS clone.
IntheJensenstudy,twoofelevenpatientshad+8;intheﬁrst,
the +8 clone decreased from 60% to 10% with chelation, and
the second had persistence of +8 and clonal evolution to a
deletion of 5q as well. Thus, immunomodulation resulting
in improvement of erythropoiesis cannot be invoked as a
predominant mechanism for transfusion independence in
these patients.
4. Conclusions
In summary, a number of patients with acquired anemias
have been reported in whom an improvement in cytopenias
was seen following the initiation of iron chelation therapy,
clinically manifested as a decrease in RBC transfusion
requirements or even transfusion independence. This may
o c c u ri nu pt o9 %o fM D S[ 41] and possible mechanisms
include reducing oxidative stress, altering intracellular levels
of NF-κB; increasing erythropoietin levels, or other mech-
anisms yet to be elucidated. In future trials of chelation,
consideration could be given to including measures of
these parameters, and conversely, trials of medications
known to induce transfusion independence in MDS such
as immunomodulatory, demethylating, or erythropoiesis
stimulating agents could compare these in responders and
nonresponders. Patients with iron overload considered for
chelation should be assessed and monitored by a physician
experienced with chelation medications.
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